Clinical Trial Update: Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study) [Phase 3]

View source ↗

Summary

Phase 3 trial EPIC-HIV, investigating PCSK9 inhibition to reduce cardiovascular risk in treated HIV infection, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Dyslipidemia
• HIV Infection

Drugs mentioned

• PCSK9 inhibitor (PCSK9 inhibitor)

Snippet

Sponsor: University of California, San Francisco | Conditions: Dyslipidemias, Cardiovascular Diseases | Phase 3 | Status: COMPLETED